Simulations Plus (SLP) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
3 Feb, 2026Executive summary
Third quarter fiscal 2024 revenue rose 14% year-over-year to $18.5 million, with strong growth in both software and services segments and adjusted diluted EPS of $0.19.
Net income for Q3 was $3.1 million, down from $4.0 million last year, primarily due to higher operating expenses.
The acquisition of Pro-ficiency was completed in June 2024 for $100 million, expanding simulation-based learning capabilities and expected to be accretive to fiscal 2025 EPS.
The Board discontinued quarterly cash dividends after August 2024 to prioritize growth investments.
Launch of next-generation PBPK modeling software GastroPlus X and new collaborations with research agencies and the FDA.
Financial highlights
Q3 revenue increased 14% year-over-year to $18.5 million; software revenue up 12% and services revenue up 18%.
Gross margin for Q3 was 71%, down from 82% last year, with software gross margin at 88% and services at 41%.
Adjusted EBITDA for Q3 was $5.7 million (31% of revenue), compared to $6.5 million (40%) last year.
Net income for the nine months ended May 31, 2024, was $9.1 million, with diluted EPS of $0.45.
Cash and short-term investments were $119 million as of May 31, 2024, prior to the Pro-ficiency acquisition.
Outlook and guidance
Fiscal 2024 guidance reaffirmed: total revenue $69M–$72M, year-over-year growth 15%–20%, software mix 55%–60%, services 40%–45%, diluted EPS $0.46–$0.48, adjusted diluted EPS $0.54–$0.56.
Pro-ficiency expected to contribute $3 million in Q4 and $15M–$18M in fiscal 2025.
Fiscal 2025 guidance to be provided in October; Pro-ficiency expected to be accretive to EPS, offsetting lost interest income.
Discontinuation of quarterly dividends will reallocate capital to growth initiatives.
Latest events from Simulations Plus
- Integrated AI ecosystem and cross-selling drive future growth, with major upside in FY 2027.SLP
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - All proposals passed with strong support; no shareholder questions were raised.SLP
AGM 202612 Feb 2026 - Virtual meeting to vote on directors, auditor, equity plan, and say-on-pay frequency.SLP
Proxy Filing4 Feb 2026 - Pro-ficiency integration and client budget trends drive growth outlook amid ongoing cost constraints.SLP
Stephens 26th Annual Investment Conference | NASH20243 Feb 2026 - $100M acquisition doubles market, expands platform, and boosts 2025 EPS outlook.SLP
M&A Announcement3 Feb 2026 - Acquisition of Pro-ficiency doubles TAM and accelerates growth in biosimulation and clinical ops.SLP
KeyBanc Capital Markets Technology Leadership Forum2 Feb 2026 - AI, cloud, and validated science converge in a unified platform to accelerate drug development.SLP
Investor Day 202623 Jan 2026 - FY24 revenue up 18% to $70M; FY25 guidance targets up to $93M and higher margins.SLP
Q4 202419 Jan 2026 - 31% revenue growth led by software, but net income fell as integration costs rose.SLP
Q1 202510 Jan 2026